Key result
Bivalirudin resolves post-LVAD native aortic valve thrombosis in a factor V Leiden patient, preventing surgery.
Why the study?
Thromboembolism remains a leading cause of mortality in patients with ventricular assist devices, and treatment strategies for aortic valve thrombosis are needed.
Case Report (n=1)
Bivalirudin may be an effective medical therapy for native aortic valve thrombosis in LVAD patients with hypercoagulable states, potentially avoiding the need for surgical intervention.
May support bivalirudin to avoid surgery in select LVAD aortic thrombosis cases; hypothesis-generating and requires prospective validation.
Ventricular assist devices are increasingly being used for mechanical support in patients with advanced heart failure. However, thromboembolism remains a leading cause of mortality in this population. We describe the successful treatment of native aortic valve thrombosis with bivalirudin in a patient with factor V Leiden mutation, who had undergone left ventricular assist device implantation, preventing the need for further surgical intervention.
No takes yet. Share an insight, caveat, or question.
Sarsam et al. (2013) conducted a case report in Native aortic valve thrombosis after left ventricular assist device implantation (n=1). Bivalirudin was evaluated on Successful treatment of native aortic valve thrombosis preventing further surgical intervention. Bivalirudin successfully treated native aortic valve thrombosis in a patient with a factor V Leiden mutation after left ventricular assist device implantation, preventing further surgical intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: